Prescription Drug News and Research

RSS

Consumers, officials work to sort out new health law

For at least one state, implementing health reform is starting to appear easier said than done. The Daily Record, a Baltimore legal newspaper, reports, "Maryland's new Health Care Reform Coordinating Council held its first meeting last week, resolving to find the best way to implement provisions of the landmark federal health care overhaul.

11 May 2010

Alexza Pharmaceuticals first-quarter net loss increases to $13.4 million

Alexza Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010 and provided a business update.

11 May 2010

PCMA releases statement on PBM Audit Reform and Transparency Act of 2010

Pharmacy benefit managers (PBMs) have pioneered tools - including incentivizing the use of generic medications, e-prescribing, and mail-service pharmacies - that improve savings, access, and safety for consumers and payers. Since the key to access is affordability, payers and policymakers alike should explore broader use of PBMs' cost-savings tools and reject approaches that make prescription drugs more expensive.

7 May 2010

Arena Pharmaceuticals reports lower net loss of $31.3 million in first-quarter 2010

Arena Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010.

7 May 2010

New changes to 'Extra Help' program enables more people save on prescription drug costs

Medicare beneficiaries who qualify for "Extra Help" may be eligible to pay no more than $2.50 for generic drugs and $6.30 for each brand name drug thanks to changes to Medicare's Low-Income Subsidy Program for Part D prescription drug costs (also known as LIS or "Extra Help") that take effect this year. These changes make it easier than ever for people on Medicare with limited incomes to save on their drug costs.

7 May 2010

M-3 Information introduces iPhone application for depression, anxiety disorders

M-3 Information entered the smart phone application environment by offering the M-3 Checklist, a scientifically validated screen for depression and anxiety disorders, at the iTunes store on Friday, April 30, 2010. Adapted from M-3 Information's existing mymoodmonitor.com website, this mobile version, called mym3, provides the same validated mental health questionnaire optimized for smart phones. A first in iPhone applications, mym3 is designed to create a bridge between user responses and recommendations set forth in the content-rich M3 website application.

7 May 2010

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

DUSA Pharmaceuticals, Inc.®, a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office has issued a notice of allowance for a key patent related to its proprietary PDT light source, the BLU-U®, Blue Light Photodynamic Therapy Illuminator.

7 May 2010

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.

6 May 2010

Aeterna Zentaris granted FDA orphan-drug designation for AEZS-108 in ovarian cancer

Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

6 May 2010

Biovail reports 27% increase in first-quarter 2010 total revenues

Biovail Corporation today announced its financial results for the three-month period ended March 31, 2010.

6 May 2010

Prescription drug may have new use in boosting effectiveness of vaccines for bacterial, viral diseases

A prescription drug already approved to treat genital warts and skin cancer may have a new use in boosting the effectiveness of future vaccines for bacterial and viral diseases, such as hepatitis C and HIV (the AIDS virus). These findings appear in ACS' Molecular Pharmaceutics, a bi-monthly journal.

6 May 2010

Alexza Pharmaceuticals secures $15M working capital loan from Hercules Technology Growth Capital

Alexza Pharmaceuticals, Inc. announced today that it has executed a $15 million working capital loan agreement with Hercules Technology Growth Capital. The funds available under the loan will be used for capital equipment and working capital purposes. In connection with the loan, Alexza issued Hercules warrants to purchase 376,394 shares of common stock at an exercise price of $2.69 per share, which was the 50-day average daily weighted average trading price at the time the term sheet for the loan was issued by Hercules.

6 May 2010

Investigations on Tylenol recall from House Committee

Following the massive recall of children’s and infants’ fever medicine Tylenol and other over the counter drugs (like Motrin, Benadryl and Zyrtec) for children a congressional committee has urged an investigation into the problem.

6 May 2010

Savient Pharmaceuticals' total revenues reach $1.1M in first-quarter 2010

Savient Pharmaceuticals, Inc. announced that its board of directors, with input from its financial advisors, has determined that a sale of Savient post-approval of KRYSTEXXA by the U.S. Food and Drug Administration (assuming KRYSTEXXA is approved) would be the best way to realize the full commercial potential of KRYSTEXXA on a global basis and would be the optimal outcome for the Company's shareholders and other stakeholders.

6 May 2010

WellCare reports GAAP net income of $6.4 million for first-quarter 2010

WellCare Health Plans, Inc. today reported results for the first quarter ended March 31, 2010. As determined under generally accepted accounting principles, the Company reported net income of $6.4 million, or $0.15 per diluted share, compared with a net loss of $36.9 million, or $0.89 per diluted share, for the prior year period. Adjusted net income for the first quarter of 2010 was $7.4 million, or $0.17 per diluted share, as compared with $12.3 million, or $0.29 per diluted share, for the same period in 2009.

5 May 2010

Meda AB's net sales for first-quarter 2010 decrease 14% to SEK 2,943M

After a strong Q4 in 2009, net sales decreased 14% in Q1 to SEK 2,943 million (3,437). Mainly currency effects but also increased competition for Astelin and Optivar reduced sales by more than SEK 400 million, compared with the same period last year.

5 May 2010

Pfizer's first-quarter 2010 revenues increase 54% to $16.8 billion

Pfizer Inc. today reported financial results for first-quarter 2010. Since the acquisition of Wyeth was completed on October 15, 2009, legacy Wyeth operations are reflected in first-quarter 2010 results, but not in first-quarter 2009 results. First-quarter 2010 revenues were $16.8 billion, an increase of 54% compared with $10.9 billion in the year-ago quarter.

5 May 2010

Alexza Pharmaceuticals announces filing of universal shelf registration statement with SEC

Alexza Pharmaceuticals, Inc. announced today that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, if declared effective by the SEC, will allow the Company to sell, from time to time, up to $75 million of its common stock, preferred stock, debt securities and/or warrants, either individually or in units, in one or more offerings.

5 May 2010

Kindred Healthcare first-quarter consolidated revenues increase 2% to $1.1 billion

Kindred Healthcare, Inc. today announced its operating results for the first quarter ended March 31, 2010. All financial and statistical information included in this press release reflects the continuing operations of the Company's businesses for all periods presented unless otherwise indicated.

5 May 2010

Catalyst Health Solutions' first-quarter 2010 net income up 26%

Catalyst Health Solutions, Inc. announces its financial results for the first quarter ended March 31, 2010. The Company reports quarterly net income of $17.4 million, up 26% from $13.8 million in the prior year. Quarterly earnings per diluted share increased to $0.39. Revenue for the quarter ended March 31, 2010, increased 18% to $832.3 million from $703.3 million in the prior year.

5 May 2010

Prescription Drug News and Research

Consumers, officials work to sort out new health law

Alexza Pharmaceuticals first-quarter net loss increases to $13.4 million

PCMA releases statement on PBM Audit Reform and Transparency Act of 2010

Arena Pharmaceuticals reports lower net loss of $31.3 million in first-quarter 2010

New changes to 'Extra Help' program enables more people save on prescription drug costs

M-3 Information introduces iPhone application for depression, anxiety disorders

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Aeterna Zentaris granted FDA orphan-drug designation for AEZS-108 in ovarian cancer

Biovail reports 27% increase in first-quarter 2010 total revenues

Prescription drug may have new use in boosting effectiveness of vaccines for bacterial, viral diseases

Alexza Pharmaceuticals secures $15M working capital loan from Hercules Technology Growth Capital

Investigations on Tylenol recall from House Committee

Savient Pharmaceuticals' total revenues reach $1.1M in first-quarter 2010

WellCare reports GAAP net income of $6.4 million for first-quarter 2010

Meda AB's net sales for first-quarter 2010 decrease 14% to SEK 2,943M

Pfizer's first-quarter 2010 revenues increase 54% to $16.8 billion

Alexza Pharmaceuticals announces filing of universal shelf registration statement with SEC

Kindred Healthcare first-quarter consolidated revenues increase 2% to $1.1 billion

Catalyst Health Solutions' first-quarter 2010 net income up 26%

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News